Neurodiagnostic technology firm Neuronetrix has obtained approval from the US Food and Drug Administration for its brain-scan device, Cognision.
Cognision measures brain activity and was in development for about ten years, reports Louisville Business First.
Neuronetrix CEO K.C. Fadem was quoted by the publication as saying that the device gathers data that can be used to assess different neurological and cognitive disorders, including Alzheimer’s disease and concussions.
"This is really the biggest hurdle in the development of any medical device," added Fadem.
According to Neuronetrix, the device is currently being used in academic, clinical, and pharmaceutical trials for a wide range of neurological disorders, across the globe.
The company also reported that the system has been used by the US Army in Afghanistan to assess the immediate cognitive effects of blast injuries sustained by front-line soldiers.